Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke

NCT07730840 · tracked via the Priya Life Science South Korea tracker

Sponsor

Asan Medical Center

Phase

Phase 3

Started

2026-10-15

Last updated

2026-10-09

Condition(s) studied

Ischemic StrokeTransient Ischemic Attack

Investigational drug(s) / intervention(s)

Zastaprazan →Placebo

Zastaprazan: Zastaprazan citrate 20 mg, a potassium-competitive acid blocker (P-CAB), administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy.

Placebo: Matching placebo for zastaprazan citrate 20 mg, administered orally once daily at a fixed dose, in addition to standard antiplatelet or anticoagulant therapy.

Study summary

The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to answer is:

\- Does zastaprazan reduce the risk of upper gastrointestinal bleeding compared to placebo in these patients?

Researchers will compare zastaprazan to a placebo (a look-alike tablet that contains no drug) to see if zastaprazan works to prevent upper gastrointestinal bleeding.

Participants will:

* Take zastaprazan (20 mg) or a placebo once daily for the duration of the study, in addition to their prescribed antiplatelet or anticoagulant medication
* Visit the study site regularly for safety monitoring, including vital signs, physical exams, and laboratory tests
* Be monitored for any signs of gastrointestinal bleeding or other adverse events for up to approximately 3 years (including screening, treatment, and follow-up periods)

Eligibility

Sex

ALL

Min age

19 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Adults aged 19 years or older 2. Onset of transient ischemic attack (TIA) or ischemic stroke within 180 days prior to randomization 3. Currently initiating or receiving, at the time of randomization, one of the following treatments, with an expected treatment duration of at least 3 weeks: A. Dual antiplatelet therapy (DAPT) - aspirin in combination with one of the following: clopidogrel, ticagrelor, prasugrel, or cilostazol B. Oral anticoagulant therapy - a NOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin 4. Provision of written informed consent by the participant (or legally authorized representative) Exclusion Criteria: 1. Clinically significant peptic ulcer or gastrointestinal bleeding within 1 year prior to enrollment 2. Moderate to severe hepatic impairment (e.g., diagnosis of cirrhosis or confirmed esophageal/gastric varices) 3. Severe thrombocytopenia (platelet count \<50,000/µL) 4. End-stage renal disease requiring dialysis, or unstable renal function precluding safe anticoagulant dose adjustment (eGFR \<15 mL/min/1.73m²) 5. Known hypersensitivity to potassium-competitive acid blockers (P-CABs) or to the investigational product 6. History of major gastrointestinal surgery resulting in malabsorption, bowel obstruction, or inability to take oral medication 7. History of osteoporotic fracture or fragility fracture 8. Diagnosis of a condition requiring long-term, high-dose systemic corticosteroid therapy 9. Diagnosis of a condition requiring long-term concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) 10. Pregnant or breastfeeding women 11. Life expectancy of less than 6 months due to pre-existing comorbid conditions 12. Current participation in another interventional clinical trial that could affect the results of this study 13. Any condition that, in the investigator's judgment, precludes participation 14. Participant or partner of childbearing/reproductive potential who does not agree to use a medically acceptable method of contraception, or to abstain from sexual activity with risk of pregnancy, during the study period 15. Currently receiving, or having received within 5 half-lives prior to randomization, a prohibited concomitant medication expected to interact with the investigational product (products containing atazanavir, nelfinavir, or rilpivirine) 16. History of peptic ulcer complications, including bleeding, perforation, or stricture, regardless of timing 17. Active bleeding at the time of enrollment, history of a coagulation disorder, or hemodynamic instability at the time of enrollment 18. Known hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

Primary outcome measure(s)

Time to First Composite Clinical Event of Upper Gastrointestinal Bleeding as Adjudicated by the Clinical Event Committee (CEC) — From randomization up to end of study (up to approximately 3 years, including a 24-month enrollment period and 12-month follow-up)
Time from randomization to the first occurrence of a composite clinical event of upper gastrointestinal (GI) bleeding, as adjudicated by the Clinical Event Committee (CEC). The composite event includes: (1) upper GI bleeding confirmed by endoscopy or imaging, with hematemesis and/or melena; (2) upper GI bleeding of unclear origin, judged by the investigator to originate from the upper GI tract; (3) occult GI bleeding, defined as a decrease in hemoglobin ≥2 g/dL or hematocrit ≥10%; (4) symptomatic uncomplicated gastroduodenal ulcer, confirmed by endoscopy or imaging with persistent pain (≥3 days) and no evidence of bleeding; (5) symptomatic gastroduodenal erosive lesions, with persistent pain (≥3 days) and ≥5 gastroduodenal erosions confirmed by endoscopy, excluding mucosal bleeding; (6) upper GI obstruction; and (7) upper GI perforation.

Trial sites (15)

Facility	City	Region
Chungnam National University Hospital	Daejeon	South Korea
Chonnam National University Hospital	Gwangju	South Korea
Ajou University Hospital	Gyeonggi-do	South Korea
Hallym University Hospital	Gyeonggi-do	South Korea
Seoul National University Bundang Hospital	Gyeonggi-do	South Korea
Uijeongbu Eulji Medical Center, Eulji University	Gyeonggi-do	South Korea
Catholic Kwandong University International St.Mary's Hospital	Incheon	South Korea
Jeju National University Hospital	Jeju City	South Korea
Jeonbuk National University Hospital	Jeonju	South Korea
Asan Medical Center	Seoul	South Korea
Ewha Womans University Seoul Hospital	Seoul	South Korea
Korea University Guro Hospital	Seoul	South Korea
Kyung Hee University Hospital	Seoul	South Korea
Samsung Medical Center	Seoul	South Korea
Yonsei University Health System, Severance Hospital	Seoul	South Korea

More Asan Medical Center trials in South Korea

BPaL(M) Regimen for the Treatment of MDR/RR-TB Recruiting

Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD Recruiting

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor Recruiting

Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients Recruiting

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH Recruiting

Other trials for the same condition

SMART-EST(Specialized Multi-center Attributed Registry of sTroke - EndovaScular or Thrombolytic Therapy) Active, not recruiting

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE Active, not recruiting

Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) Recruiting

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke Recruiting

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07730840 on ClinicalTrials.gov ↗ ← All trials in South Korea